CollPlant Holdings

US: CLGN

NIS75m market cap

NIS0.43 last close

CollPlant is an Israel-based regenerative medicine company. It is focused on developing and commercializing tissue repair products with its plant-based technology, rhCollagen. It has two products on the market, VergenixSTR and Vergenix FG, and has received several orders for its 3D bioprinting product bioInk.

Investment summary

Edison Investment Research is terminating coverage on CollPlant Holdings (CLGN). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Dec
Revenue (NISm)
EBITDA (NISm)
PBT (NISm)
EPS (NIS)
P/E (x)
P/CF (x)
2016A 0.3 (27.0) (27.9) (27.72) N/A N/A
2017A 1.7 (19.7) (20.9) (15.68) N/A N/A
2018E 21.1 (11.8) (12.7) (6.10) N/A N/A
2019E 7.3 (18.7) (20.1) (8.57) N/A N/A
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (NISm) 18.7
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 12.63 (9.32) (19.85)
Relative* 17.541 (10.614) (25.781)
52-week high/low NIS0.6/NIS0.4
*% relative to local index
Key management
Yehiel Tal CEO
Eran Rotem CFO